Concurrent de novo MET amplification may be found in 2–8% of EGFRm+ NSCLC patients prior to EGFR-TKI therapy and may represent a potential mechanism of intrinsic resistance to EGFR-TKIs [6,20,32,66,85,86,87]. Here, EGFR is linked to non-small cell lung carcinoma.